SEOUL, KOREA | Adelaide, Australia
Avance Clinical, a
leading full-service global Contract Research Organization (CRO) known for delivering high-quality,
agile clinical research services, is proud to announce the signing of three significant Memorandums of
Understanding (MOUs) with key Korean clinical sites during KoNECT 2024 conference.
Avance
Clinical CEO Yvonne Lungershausen and
Asia Regional Director Jessica Han, attended the KoNECT conference, and the three
clinical sites to sign these partnerships, marking an important milestone in the company’s strategic
expansion across the Asia-Pacific region.
Avance Clinical is a mid-sized CRO with a proven
track record of swiftly advancing quality clinical biotech programs. The CRO is highly regarded among
US-based biotechs which make up more than 80% of its clients.
Yvonne Lungershausen, Avance Clinical CEO, and Young-Sang Kim, Director
of CHA Global Clinical Trials Center (CHA University Bundang Medical Center), signed
the MOU in Seoul, South Korea this week.
Lungershausen stated, “These new MOUs further strengthen our mission to
provide world-class services to international biotech clients. As Avance Clinical
continues to grow its global footprint, these partnerships with respected
institutions will further enhance our ability to offer flexible, efficient, and
high-quality clinical trial services in the Asia-Pacific region.”
Jessica
Han, based in Seoul, said “With its highly sophisticated healthcare infrastructure and
regulatory framework, South Korea offers an ideal environment for clinical trials. These
MOU signings will not only solidify our collaborations with key institutions but also
provide our clients with seamless access to high-quality clinical trial sites and
patient populations in the region. We look forward to forging deeper connections and
driving growth in
Asia.”
The MOUs were signed with
CHA University Bundang Medical Center an
advanced 1,000 bed hospital with a focus on patient care, research
and education. Designated as a Research-Driven Hospital, it is
committed to delivering a stable research environment and
infrastructure to support the latest research and state-of-the-art
medical technology. This partnership with Avance Clinical will
further the reach and impact the hospital has on healthcare
development globally.
Signed on October 28,
2024
Young-Sang Kim, Director for CHA Global Clinical
Trials Center (CHA University Bundang Medical Center)
shared his enthusiasm for the collaboration, remarking, “Partnering
with Avance Clinical presents a valuable opportunity to expand our
clinical trial expertise, especially in early-phase research. We
believe this collaboration will not only strengthen our capabilities
but also enable us to offer cutting-edge therapeutic solutions that
will impact patients on a global scale”.
Korea
University Medicine (Seoul), is a leading academic and
medical institution recognized for its robust clinical trial
capabilities. This partnership aims to accelerate clinical research
opportunities, leveraging Korea University Medicine’s expertise to
drive the development of innovative therapeutics.
Signed on October 29, 2024
Hak Jun Kim, President for Medical Research & Business
Foundation of Korea University Medicine expressed
optimism about the partnership, stating, “We look forward to
collaborating with Avance Clinical, a global CRO, and this MOU marks
an important starting point to further enhance our unique strengths.
We anticipate maintaining a close relationship to play a leading
role in the clinical trial field”.
Dong-A
University Hospital, Clinical Trial Center (Pusan) is
known for its comprehensive clinical trial infrastructure and
experienced research teams. The collaboration with Dong-A aims to
deepen research ties, particularly in early-phase clinical trials,
offering expanded opportunities for clients seeking to develop
breakthrough therapies across multiple therapeutic areas.
Signed on October 30, 2024
Sung Yong Oh, Director of the Dong-A University
Hospital, Clinical Trial Center expressed confidence in
the newly formed collaboration, stating, “This partnership with
Avance Clinical marks a pivotal moment for us. By working together,
we can further enhance our research infrastructure and significantly
contribute to global healthcare innovations. We are confident that
this collaboration will accelerate the development of advanced
medical technologies and treatments”.
The MoU signings and
Avance Clinical’s participation in KoNECT reflect the company’s
ongoing commitment to expanding its global footprint. KoNECT 2024,
co-hosted by the Korea National Enterprise for Clinical Trials
(KoNECT) and the Ministry of Health and Welfare (MOHW), is a premier
event for thought leaders and industry professionals to discuss
innovations in clinical trials across the Asia-Pacific region.
